Publications
306
Citations
2,630
Est. group size
~50
Recurring co-author estimate
Active years
18
Publishing since 2009
Jonathan E. Brammer's research focuses on blood cancers, particularly lymphomas and leukemias, and their treatment using stem cell transplantation and CAR T-cell therapy (a treatment that engineers a patient's immune cells to attack cancer). His work includes clinical trials of new drugs, studies of treatment side effects and safety, and analyses of patient outcomes to improve care for people with these diseases.
Publication output has grown substantially over the past decade, rising from single digits in 2017-2018 to a sustained pace of roughly 30-50 papers per year since 2023.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Safety and Immunomodulatory Effects of Siltuximab Prophylaxis Prior to Standard of Care CD19 Directed Chimeric Antigen Receptor T-cell (CD19.CART) Therapy for B-cell Lymphomas: Final Phase I Trial Results
Transplantation and Cellular Therapy · 2026
- Sustained Expansion of CAR-Negative T cells Correlates with Improved Outcomes after CD19 CAR T-cell Therapy in Lymphoma
Transplantation and Cellular Therapy · 2026
- Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate
Journal of Oncology Pharmacy Practice · 2026
- Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia
Leukemia · 2026
- Reversible cerebral vasoconstriction syndrome following ciltacabtagene autoleucel therapy for relapsed multiple myeloma: a case report
Frontiers in Immunology · 2026
- Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma
Journal of Clinical Oncology · 2026
- Allogeneic Stem Cell Transplant Results in T-cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
Transplantation and Cellular Therapy · 2026
- Anti-CD19 Chimeric Antigen Receptor T-cell Therapy for Patients with Non-Hodgkin's Lymphoma and Concurrent Autoimmune Disease
Transplantation and Cellular Therapy · 2026
- Bone Marrow Involvement in Sarcoidosis: A Case Report of Granulomatous and Hematologic Complications
Clinical Case Reports · 2026
- Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
Journal of Hematology & Oncology · 2025
- Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network · 2025
- ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome
Journal of the American Academy of Dermatology · 2025
- Acute kidney injury after chimeric antigen receptor T‐cell therapy is associated with inferior survival in patients with relapsed/refractory large B‐cell lymphoma
British Journal of Haematology · 2025
- Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma
Transplantation and Cellular Therapy · 2025
- 766 | OUTCOMES OF PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA BY RACE/ETHNICITY AND CLINICAL TRIAL ENROLLMENT
Hematological Oncology · 2025
- Blood×82
- Transplantation and Cellular Therapy×27
- Biology of Blood and Marrow Transplantation×13
- Hematological Oncology×12
- Blood Advances×10
- Walter Hanel
Medicine · The Ohio State University
- Basem M. William
Medicine · The Ohio State University
- Zachary Braunstein
Medicine · The Ohio State University
- John Reneau
Medicine · The Ohio State University
- Narendranath Epperla
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile